Nine-year follow-up of lenalidomide plus rituximab as initial treatment for mantle cell lymphomaSamuel Yamshon, Jia Ruan, Gui Zhen Chen et al.|Blood Advances|2023Cited by 10
MRD-driven initial therapy of acalabrutinib and lenalidomide plus rituximab or obinutuzumab for mantle cell lymphomaJia Ruan, Peter W. Martin, Sarah C. Rutherford et al.|Blood Advances|2025Cited by 3